NDAORALTABLET
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Clinical Trials (5)
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Started Aug 2021
8 enrolled
EpilepsyEpilepsy in ChildrenEpilepsy; Seizure+5 more
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Started Mar 2021
8 enrolled
EpilepsyEpilepsy in ChildrenEpilepsy; Seizure+5 more
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Started Jun 2015
65 enrolled
Amyotrophic Lateral Sclerosis
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
Started Mar 2013
10 enrolled
Epilepsy
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
Started Dec 2012
6 enrolled
Seizures